Intravenous Iron in Inflammatory Bowel Disease: Closing Outcomes Chasms through the Effective Management of Iron Deficiency Anemia

Wednesday, December 7, 2022

12:30 PM – 1:30 PM

Location: Northern Hemisphere C

Speaker(s)

Millie D. Long, MD, MPH, FACG

Professor of Medicine
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Gary R. Lichtenstein, MD, FACG

Professor of Medicine , Director Center for IBD, University of Pennsylvania Health System
University of Pennsylvania
Philadelphia, Pennsylvania
Neilanjan Nandi, MD, FACP

Associate Professor of Clinical Medicine
University of Pennsylvania, Penn Presbyterian
Garnet Valley, Pennsylvania

This symposium is supported by an independent educational grant from Creative Educational Concepts; Supported by an independent educational grant from American Regent, Inc.

12:30 PM Welcome and Introductions/Pre-test
Neilanjan Nandi, MD, FACP (Activity Chair)

12:35 PM IDA in IBD: The Etiology, Epidemiology, and Pivotal Impact of Inflammation on Functional Iron Deficiency
Millie D. Long, MD, MPH

12:50 PM What’s New and What’s Next: The Established Paradigm and the Evolving Evidentiary Base for Next-generation IV Iron Therapies in IBD
Gary R. Lichtenstein, MD

1:05 PM Gastroenterology Expert Exchange—Data-driven Discussions of Hyperinflammation, Hepcidin, and Real-world Implications for IV Iron in IBD Clinical Case Discussion, Post-test and Q&A
All Faculty, moderated by Neilanjan Nandi, MD, FACP

Learning Objectives:

Discuss the basic principles of iron metabolism and absorption, including the practical distinctions between functional and absolute iron deficiency, with a focus on how these principles apply to IDA treatment in IBD.
Evaluate the role of iron deficiency as an etiology for anemia in IBD.
Recognize the prevalence of comorbid IBD and IDA and describe the substantial impact of anemia on IBD patient-reported quality-of-life metrics and clinical outcomes.
Review the essential utility of serum ferritin, transferrin saturation (TSAT), and C-reactive protein as diagnostic laboratory indices, alongside hemoglobin, for IDA in IBD.
Examine the pathophysiologic principles of how inflammation and hepcidin affect iron availability and utilization, especially in an intrinsically hyperinflammatory condition like IBD, and the resultant rationale for preferential treatment with IV iron vs oral iron.
Identify how next-generation IV iron products have improved upon the safety and efficacy profiles of older agents, with emphasis on dramatically reduced rates of severe hypersensitivity reactions, especially in the setting of IBD.
Appraise completed, ongoing, and planned clinical trials of IV iron therapies for IDA management in IBD.
Compare and contrast FDA-approved IV iron products, including new indications and dosing regimens.
Identify how next-generation IV iron products have improved upon the safety and efficacy profiles of older agents, with emphasis on dramatically reduced rates of severe hypersensitivity reactions, especially in the setting of IBD.
Design innovative, evidence-supported clinical tools that can interface with institutional EHRs, such as diagnostic algorithms, digitalized checklists to promote IBD GDMT, and Ganzoni’s formula to determine iron repletion dosages.